The initiation of the Phase 1 trial for GT-02287 represents a significant milestone for Gain Therapeutics. The successful completion of this trial could potentially lead to a new treatment for GBA1 Parkinson's disease, which would significantly boost the company's product portfolio and potentially its stock price. However, the results are not expected until the first half of 2024, which introduces a degree of uncertainty and risk.